Application of combination of STK39 inhibitor and chemoradiotherapy or PARPi in tumor treatment

Through the combined use of STK39 inhibitors with radiotherapy, chemotherapy or PARPi, the sensitivity of tumor cells to treatment is enhanced, the problem of limited therapeutic effect of PARPi in the prior art is solved, effective treatment of tumors other than BRCA mutations is achieved, and the Treatment suitability.

CN118903425APending Publication Date: 2024-11-08CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410954979.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, PARPi treatment has limited efficacy in tumor patients carrying BRCA1/2 mutations, and the application of STK39 inhibitors in tumor treatment has not been studied, which limits the effectiveness and applicability of tumor treatment.

Method used

STK39 inhibitors are used alone or in combination with radiotherapy, chemotherapy or PARPi to enhance anti-tumor effects, break through the limits of BRCA gene mutation, expand the indications of PARPi, reduce DNA repair ability by inhibiting STK39 activity, and enhance the sensitivity of tumor cells to treatment. .

Benefits of technology

STK39 inhibitors significantly enhance the anti-tumor effects of radiotherapy, chemotherapy and PARPi, expand the applicability of PARPi, enable more patients to benefit, and have less toxic side effects and easy absorption.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903425A_ABST
    Figure CN118903425A_ABST
Patent Text Reader

Abstract

The invention provides a medicinal application of an STK39 inhibitor alone or in combination with radiotherapy, chemotherapy or PARPi for treating various tumors, and relates to the technical field of biological medicines. According to the invention, the novel pharmaceutical application of the STK39 inhibitor (including ZT-1a and Rafoxide) is provided for the first time, in-vitro and in-vivo experiments prove that the STK39 inhibitor can be used for treating various tumors independently or in combination with radiotherapy, chemotherapy (cis-platinum and etoposide) or PARPi, and the cancers are pancreatic cancer, ovarian cancer and liver cancer. The invention has the technical effects that a new medicine application of independent application of the STK39 inhibitor is added, the gene mutation limitation of PARPi in tumor treatment is broken through, the adaptation diseases of PARPi in patients with pancreatic cancer and ovarian cancer are expanded, and the effects of conventional anti-tumor treatment such as radiotherapy and chemotherapy are enhanced by combined medication, so that the tumor patients can gain more benefits from the PARPi. The invention develops a new pharmaceutical application for the STK39 inhibitor, and also lays an experimental foundation and provides a new view for developing an efficient anti-tumor combined therapy scheme.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and specifically to the use of STK39 inhibitors in combination with radiotherapy and chemotherapy or PARPi in tumor treatment. Background Art

[0002] DNA damage repair coordinates the cell's response to DNA damage through complex mechanisms, maintaining the integrity and stability of cell genes. Among them, homologous recombination repair (HRR) and non-homologous end joining (NHEJ) are key to repairing DNA double-strand breaks to ensure cell survival. HRR, as a high-fidelity DNA repair pathway, is a key regulator of cancer cell survival and chemotherapy resistance. Targeted inhibition of key components of the HRR pathway is a feasible method to induce cancer cell death, and combined with radiotherapy, chemotherapy or other targeted therapies is believed to enhance the anti-tumor effect.

[0003] BRCA1 / 2 mutations impair HRR, making cells highly sensitive to PARPi. However, less than 10% of tumor patients carrying BRCA1 / 2 mutations can benefit from PARPi treatment, limiting its wider application in tumor treatment. Other prior art solutions related to the purpose of the present invention include the use of PARPi alone to treat tumors (CN110087730B, CN102341394B). However, the efficacy of a single PARPi treatment regimen is limited. STK39 inhibitors can treat cerebral edema in animal experiments (US11414379B2), and there are no related research reports on their application in tumor treatment. Summary of the invention

[0004] In view of the defects of the prior art, the purpose of the present invention is to provide a drug use of STK39 inhibitors alone or in combination with radiotherapy, chemotherapy or PARPi for treating tumors. Through in vitro and in vivo experiments, it is proposed for the first time that STK39 inhibitors alone or in combination can be used to treat tumors. The technical effect of the present invention adds new drug uses of STK39 inhibitors alone, such as enhancing the anti-tumor effect of radiotherapy or chemotherapy, and breaking through the BRCA gene mutation restrictions in tumor treatment, expanding the indications of PARPi, and enhancing the efficacy of PARPi with combined medication, so that patients can benefit more from it.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions.

[0006] The invention discloses the use of a STK39 inhibitor as the sole active ingredient in preparing a medicine for treating tumors.

[0007] The invention also discloses the use of the STK39 inhibitor as the only active ingredient in the preparation of a drug for inhibiting the proliferation and invasion ability of tumor cells.

[0008] Furthermore, the STK39 inhibitor in any of the above applications includes ZT-1a, Rafoxanide or shRNA; the shRNA nucleotide sequence is as shown in SEQ ID No. 1-2.

[0009] The present invention also discloses a pharmaceutical composition, characterized in that the pharmaceutical composition comprises a STK39 inhibitor and a PARP inhibitor.

[0010] The present invention also discloses a pharmaceutical composition, characterized in that the pharmaceutical composition comprises a STK39 inhibitor and a chemotherapeutic drug.

[0011] Furthermore, the STK39 inhibitor includes ZT-1a, Rafoxanide or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-2.

[0012] The present invention also discloses a pharmaceutical preparation, characterized in that the pharmaceutical preparation comprises a STK39 inhibitor or a combination of a STK39 inhibitor and a PARP inhibitor or a combination of a STK39 inhibitor and a chemotherapeutic drug.

[0013] The present invention also discloses a radio / chemotherapy sensitizer, characterized in that it comprises a STK39 inhibitor.

[0014] Furthermore, the STK39 inhibitor described in any one of the above items includes ZT-1a, Rafoxanide or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-2.

[0015] Furthermore, use of any of the above-mentioned pharmaceutical compositions, pharmaceutical preparations or radio / chemotherapy sensitizers in the preparation of drugs for treating tumors.

[0016] The present invention identifies serine / threonine kinase 39 (STK39, also known as SPAK, a member of the Ste20-like kinase family) as a new important target in the HRR pathway. After DNA damage, STK39 is phosphorylated by ATM and then recruited to the damage site. By promoting the phosphorylation of H2A.X, STK39 amplifies the γH2A.X signal and enhances the HRR ability. Mechanistically, inhibiting STK39 activity can reduce the formation of γH2A.X phosphorylated by STK39, ultimately inhibiting the ability to repair DNA double-strand breaks, and producing a synergistic lethal effect with other anti-tumor treatments. The present invention also proves that STK39 inhibitors can indeed enhance the sensitivity of tumors to radiotherapy, chemotherapy and PARPi treatment. For example, in liver cancer and pancreatic cancer, STK39 inhibitors enhance the anti-tumor effects of radiotherapy and chemotherapy. The mechanism is that radiotherapy, cytotoxic drugs, etc. kill tumor cells by destroying DNA structure, while STK39 inhibitors weaken the HRR ability, so that the damaged DNA cannot be repaired and promote tumor cell death. Based on the synergistic lethal effect, STK39 inhibitors combined with PARPi overcome the limitations of PARPi treatment in pancreatic cancer and ovarian cancer, and can benefit a wider range of tumor patients beyond BRCA mutations. Currently, no STK39 inhibitors have been approved for the treatment of tumors. The present invention shows that the combination of STK39 inhibitors is a promising therapeutic strategy to enhance the sensitivity of anti-tumor therapy.

[0017] The purpose of the present invention is to provide a new method for treating tumors, aiming to improve the anti-tumor efficacy. The technical solution is to use a combination of STK39 inhibitors combined with chemoradiotherapy or PARPi to treat tumors. Through combined treatment, tumor cell vulnerability can be caused from different angles at the same time, enhancing the anti-tumor effect of chemoradiotherapy, while expanding the applicability of PARPi treatment beyond the limitations of BRCA mutation status.

[0018] Compared with the prior art, the beneficial effects of the present invention are as follows.

[0019] 1. STK39 inhibitors are small molecule compounds that are oral and easy to use, absorb and distribute, and some can pass through the blood-brain barrier.

[0020] 2. The effective dose of combined STK39 inhibitor is small, metabolism is rapid, and toxic side effects may be small.

[0021] 3. STK39 inhibitors have a narrow spectrum of action and a low off-target rate, and are less likely to cause other toxic side effects.

[0022] 4. STK39 inhibitors can significantly enhance the killing ability of PARPi.

[0023] 5. STK39 inhibitors can significantly enhance the killing ability of radiotherapy.

[0024] 6. STK39 inhibitors can significantly enhance the killing ability of chemotherapy, including cisplatin and etoposide.

[0025] 6. STK39 inhibitors can lower blood pressure and have certain effects on patients with hypertension. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 STK39 regulates HRR function. Among them, (A) is the knockdown of STK39 in cells using short hairpin RNA (shRNA) targeting STK39, and the knockdown efficiency of the indicated antibodies was evaluated by western blot. (B) is a schematic diagram of the fluorescence reporter assay for quantitative evaluation of HRR activity. (C) is the effect of knocking down STK39 in cells on HRR efficiency. (D) is a schematic model of the HRR molecular signaling cascade. (EN) is the effect of knocking down STK39 on ionizing radiation-induced lesion formation. (OP) is the comet assay analysis of the effect of knocking down STK39 on DNA damage levels. (QR) is the effect of knocking down STK39 on the sensitivity of cells to DNA damaging factors. (S) is a schematic diagram of the molecules regulated by STK39 in the HRR signaling pathway. Error bars represent the standard error of the mean (sem). Unpaired T test was used, and the significance level was marked as *P<0.05, **P<0.01, ***P<0.001. NS means no significant change. Note: HRR: homologous recombination repair; IR: irradiation.

[0027] Figure 2 The inhibitory effect of STK39 inhibitors on STK39 activity. Among them, (A) is the western blot detection of the inhibitory effect of different doses of STK39 inhibitors on STK39 activity. (B) is the analysis of the efficiency of STK39 inhibitors in inhibiting HRR in cells treated with different doses of STK39 inhibitors. (CL) is the effect of different doses of STK39 inhibitors on inhibiting STK39 activity to reduce the formation of lesions induced by ionizing radiation. (MN) is the comet assay to analyze the effect of different doses of STK39 inhibitors on the level of cellular DNA damage. (OP) is the effect of STK39 inhibitors on the sensitivity of cells to DNA damaging factors. Error bars represent the standard error of the mean (sem). Unpaired T test was used, and the significance level was marked as *P<0.05, **P<0.01, ***P<0.001. NS indicates no significant change. Note: HRR: homologous recombination repair; IR: irradiation.

[0028] Figure 3 The effects of STK39 inhibitors on chemotherapy of ovarian cancer and liver cancer cells. Among them, (AB) shows that the STK39 inhibitor ZT-1a affects the sensitivity of liver cancer cell HuH-7 to cisplatin (A) and etoposide (B) chemotherapy. (CD) shows that the STK39 inhibitor ZT-1a affects the sensitivity of liver cancer cell Hep3B to cisplatin (C) and etoposide (D) chemotherapy. (EF) shows that the STK39 inhibitor ZT-1a (E) and Rafoxanide (F) affect the sensitivity of ovarian cancer cell A2780 to cisplatin chemotherapy. (GH) shows that the STK39 inhibitor ZT-1a (G) and Rafoxanide (H) affect the sensitivity of ovarian cancer cell A2780 to etoposide chemotherapy. (IJ) shows that the STK39 inhibitor ZT-1a (I) and Rafoxanide (J) affect the sensitivity of ovarian cancer cell OVCAR-8 to cisplatin chemotherapy. (KL) STK39 inhibitors ZT-1a (K) and Rafoxanide (L) affect the sensitivity of ovarian cancer cells OVCAR-8 to etoposide chemotherapy. (MN) STK39 inhibitors ZT-1a (M) and Rafoxanide (N) affect the sensitivity of ovarian cancer cells HO-8910 to cisplatin chemotherapy. (KL) STK39 inhibitors ZT-1a (K) and Rafoxanide (L) affect the sensitivity of ovarian cancer cells OVCAR-8 to etoposide chemotherapy. Error bars represent standard error of the mean (sem).

[0029] Figure 4 The effects of STK39 inhibitors on radiotherapy of pancreatic cancer cells. (A) The STK39 inhibitor ZT-1a increases the sensitivity of pancreatic cancer cells PANC-1 to radiotherapy-induced DNA damage. (B) The STK39 inhibitor ZT-1a increases the sensitivity of pancreatic cancer cells SW1990 to radiotherapy-induced DNA damage.

[0030] Figure 5The effects of STK39 inhibitors on the PARPi effect of pancreatic cancer and ovarian cancer cells. Among them, (A) shows that the STK39 inhibitor ZT-1a increases the sensitivity of pancreatic cancer cells PANC-1 cells to Olaparib. (B) shows that the STK39 inhibitor ZT-1a increases the sensitivity of pancreatic cancer cells SW1990 cells to Olaparib. (CD) shows that the STK39 inhibitor ZT-1a (C) and Rafoxanide (D) affect the sensitivity of ovarian cancer cells A2780 to Olaparib. (EF) shows that the STK39 inhibitor ZT-1a (E) and Rafoxanide (F) affect the sensitivity of ovarian cancer cells OVCAR-8 to Olaparib. (GH) shows that the STK39 inhibitor ZT-1a (G) and Rafoxanide (H) affect the sensitivity of ovarian cancer cells HO-8910 to Olaparib.

[0031] Figure 6 Figure 1. Inhibition of STK39 sensitizes pancreatic cancer to PARPi in a pancreatic cancer mouse CDX model. (AC) STK39 inhibitor sensitizes PANC-1 cell-derived xenograft model (CDXs) to olaparib; (A) tumor growth curve, (B) representative images, (C) tumor weight. (DF) STK39 inhibitor sensitizes SW1990 CDXs to olaparib; (D) tumor growth curve, (E) representative images, (F) tumor weight. (GI) Inhibition of STK39 by STK39 inhibitor reduces Ki-67 positive staining and increases cleaved caspase-3 staining in PANC-1 CDXs treated with olaparib. (JL) Inhibition of STK39 by STK39 inhibitor reduces Ki-67 positive staining and increases cleaved caspase-3 staining in SW1990 CDXs treated with olaparib. Data points with error bars represent mean ± standard error (sem). p values ​​were calculated by T-test. *P<0.05, **P<0.01, ***P<0.001, NS, no significant change.

[0032] Figure 7Figure 1. Inhibition of STK39 sensitizes pancreatic cancer to PARPi in pancreatic cancer mouse PDX models. (AC) STK39 inhibitor sensitizes 893 patient-derived xenograft models (PDXs) to olaparib; (A) tumor growth curve, (B) representative image, and (C) weight. (DF) STK39 inhibitor sensitizes PDX-848 model to olaparib; (D) tumor growth curve, (E) representative image, and (F) tumor weight. (GI) Inhibition of STK39 by STK39 inhibitor reduces Ki-67 positive staining and increases cleaved caspase-3 staining in PDX-893 treated with olaparib. (JL) Inhibition of STK39 by STK39 inhibitor reduces Ki-67 positive staining and increases cleaved caspase-3 staining in PDX-848 treated with olaparib. (P, Q) Changes in body weight of four groups of PDX-893 (n = 6) or PDX-848 (n = 5) mice treated with STK39 inhibitors. Error bars represent standard error of the mean (SEM). Unpaired T-test was used, and the significance levels are marked as *P < 0.05, **P < 0.01, ***P < 0.001. DETAILED DESCRIPTION

[0033] The present invention is further described in detail below with specific embodiments, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following embodiments, and all technologies realized based on the content of the present invention belong to the scope of the present invention.

[0034] Unless otherwise specified, all reagents and materials used in the present invention are commercially available.

[0035] 1. Materials and methods.

[0036] 1. Homologous recombination ability experiment.

[0037] The efficiency of homologous recombination repair of DNA double-strand breaks was evaluated using the DR-GFP reporter system. Blank, 293T cells stably expressing WT STK39 and shRNA (as shown in SEQ ID NO.1-2 below) were seeded into each well of a six-well plate three times. Within 24 hours, cells in each well were transfected with Lipofectamine mixed with plasmids containing 500ng DR-GFP, 50ng mCherry and 500ng I-Sce1. STK39 inhibitor (ZT-1a) was added to the culture medium 8 hours after blank cell transfection. 48 hours after transfection, cells were collected for flow cytometry analysis (FACS). The relative percentage of mCherry / GFP positive cells was calculated by dividing the number of mCherry / GFP positive cells by the number of mCherry single positive cells.

[0038] shRNA1 (SEQ ID No. 1) GTACGGCAAGTCCTTTAGAAATTCAAGAGATTTCTAAAGGACTTGCCGTACTTTTTT.

[0039] shRNA2 (SEQ ID No. 2) CGGTCAGATTCACAGGGATTTTCAAGAGAAATCCCTGTGAATCTGACCGTTTTTT.

[0040] 2. Immunofluorescence experiment of DNA damage foci formation.

[0041] U2OS cell lines stably expressing WT STK39 or shRNA, and U2OS cells treated with STK39 inhibitor (ZT-1a) were exposed to X-ray irradiation (1 Gy). After 1 h, the cells were washed with 1× PBS, fixed with 4% formaldehyde for 15 min, permeabilized with 0.5% TritonBuffer for 10 min, blocked with 5% goat serum for 1 h, and incubated with primary antibodies (γH2A.X, MDC1, FK2, 53BP1, and BRCA1, diluted 1:1000 in 5% goat serum) overnight. Subsequently, the cells were washed three times with 1× TBST, treated with secondary antibodies (donkey anti-rabbit IgG Alexa Fluor 594 and donkey anti-mouse IgG Alexa Fluor 488 from Invitrogen, diluted 1:200 in 5% goat serum) at 37°C for 20 min, co-stained with DAPI (Invitrogen), and observed under a fluorescence microscope. The number of nuclear foci signals was quantified using ImageJ, and at least 100 cells were counted for each cell line.

[0042] 3. Clone formation assay.

[0043] Cells were seeded in 6-well plates at a concentration of 500-1000 cells per well. The next day, cells were treated with different doses of STK39 inhibitor, olaparib, or X-rays (1, 2, 4, 8 Gy). Culture was continued for 10-14 days, and then the colonies were stained with 0.1% crystal violet solution. The number of colonies in each well was quantified, and the survival fraction was calculated by comparing the number of colonies in the treated wells with the number of colonies in the untreated wells.

[0044] 4. Cell viability assay.

[0045] Cell viability was measured using the Cell Counting Kit-8 (CCK-8) assay (Vazyme, Nanjing, China). Approximately 2 × 10 4cells. Cisplatin (Invitrogen, USA), etoposide (Invitrogen, USA), and STK39 inhibitor (ZT-1a or Rafoxanide) were dissolved in DMSO, diluted in growth medium, and added to the wells for incubation for 72 h. Then, 10 μL of CCK-8 reaction solution was added to each well according to the manufacturer's protocol, and the optical density (OD) value at 450 nm of each well was measured.

[0046] 5. Comet experiment.

[0047] U2OS cells pretreated with STK39 inhibitor (ZT-1a, 0 μM, 2 μM, 4 μM) for 1 h and stable U2OS cell lines expressing WTSTK39 and shRNA were irradiated (10 Gy). Then, the cells were gently scraped and irradiated with 1×10 5 Cells were resuspended in cold PBS at a concentration of 10 cells / mL, and then the cells were combined with molten LMAgarose at a ratio of 1:10 (v / v), and 100 μL was immediately pipetted onto the Comet Slide. The slide was placed flat in the dark at 4°C for 10 minutes, immersed in pre-cooled lysis buffer, and allowed to stand at 4°C for 1 hour. The slide was then placed in pre-cooled neutral electrophoresis buffer for 30 minutes at 4°C and then transferred to the electrophoresis instrument for TBE electrophoresis. The sample was soaked in 70% ethanol at room temperature for 30 minutes, dried, and placed in 50 μL of diluted propidium iodide in the dark for 30 minutes. Images were recorded by fluorescence microscopy and analyzed using CometScore software.

[0048] 6. Validation of pancreatic cancer cell-derived and patient-derived xenograft models.

[0049] The cell-derived xenograft (CDX) model was established using 5-6 week-old female thymic nude mice (BALB / c-nu). 6A suspension of pancreatic cancer cells (pancreatic cancer cell lines with high expression of STK39, including PANC-1 and SW1990) was mixed with 50% Matrigel to make a 100 μL suspension, which was subcutaneously injected into the armpit of each mouse. About 12 days after inoculation, the mice were divided into different treatment groups, including STK39 inhibition group (STK39 inhibitor, 20 mg / kg, intraperitoneal injection, once every other day for two weeks), olaparib group (20 mg / kg, intraperitoneal injection, once every other day for two weeks) and STK39 inhibitor and olaparib combination treatment group (STK39 inhibitor 20 mg / kg combined with olaparib 20 mg / kg, intraperitoneal injection, once every other day for two weeks), with 5 to 6 mice in each group. Pancreatic cancer patient-derived xenograft (PDX) models were obtained from Nanchang Luoyao Biotechnology Co., Ltd. Models with high expression of stk39 (PDX-893 and 848) were selected for explantation. Biopsies of PDX tumors were implanted subcutaneously into BALB / c-nu female mice. Once the mean tumor volume of the PDX model reached 200 mm 3 Mice were randomly assigned to treatment cohorts, including a control group that received blank placebo only, STK39 inhibitor (STK39 inhibitor, 20 mg / kg, intraperitoneal injection, every other day for two weeks), olaparib (20 mg / kg, intraperitoneal injection, every other day for two weeks), and a combination of STK39 inhibitor and olaparib.

[0050] In all mouse studies, the length and width of each tumor were measured every other day using electronic calipers. Tumor volume was calculated using the formula: volume = 0.5 (length × width 2 ). At the end of the experiment, the animals were euthanized, and part of the tumor tissue was quickly fixed in 4% paraformaldehyde for immunohistochemistry (IHC) analysis, and the rest of the tumor tissue was stored at -80°C. Tumor tissues of CDX and PDX were collected for immunohistochemical staining. Fresh tumor tissues were fixed with 4% paraformaldehyde fixative overnight, dehydrated and embedded in paraffin. Samples were subjected to immunohistochemical staining. Primary antibodies included Ki67 and Caspase-3. Images were obtained at 200x magnification and semi-quantitative evaluation was performed using an immunoreactivity scoring system.

[0051] 2. Experimental results.

[0052] 1. Cell experiments have shown that knocking down STK39 weakens the ability of homologous recombination repair.

[0053] Figure 1 A shows that two independent shRNAs can knock down endogenous STK39 in cells. DNA repair efficiency was examined by HRR reporter system ( Figure 1 B) The results showed that HRR efficiency was reduced after STK39 gene knockout ( Figure 1 C). These data suggest that STK39 is involved in the cellular response to DNA damage. HRR signaling recruits a series of DNA repair factors, including γ-H2A.X, MDC1, RNF8, RNF168, and BRCA1 ( Figure 1 D). STK39 deficiency significantly impaired the foci formation of all these DNA repair factors ( Figure 1 EN). Comet assays also showed that the effect of STK39 on DNA repair pathways was not caused by changes in DNA damage levels ( Figure 1 OP). U2OS cells with knockdown of STK39 showed increased sensitivity to radiation and olaparib ( Figure 1 Q and R). These results suggest that STK39 regulates the HRR pathway ( Figure 1 S), knockdown of STK39 reduced the HRR ability of cells.

[0054] 2. Cell experiments have shown that STK39 inhibitors reduce the efficiency of homologous recombination repair.

[0055] STK39 inhibitors led to a significant decrease in phosphorylation of STK39 Ser373 (the activation site phosphorylated by WNK142), indicating that STK39 inhibitors effectively inhibited its kinase activity ( Figure 2 A). STK39 inhibitors inhibit STK39, resulting in reduced HRR efficiency in cells ( Figure 2 B), and also reduced the formation of foci of molecules in the HRR pathway (γ-H2A.X, MDC1, RNF8, RNF168, and BRCA1) ( Figure 2 CL). Moreover, treatment of cells with STK39 inhibitors did not lead to an increase in the comet tail moment, indicating that STK39 inhibitors did not change the level of DNA damage ( Figure 2 MN). Correspondingly, clonogenic assays showed that STK39 inhibitors sensitized cells to radiation and olaparib ( Figure 2 OP).

[0056] 3. Cell experiments have shown that STK39 inhibitors can enhance the chemotherapy effects of cisplatin or etoposide in ovarian cancer and liver cancer cells.

[0057] The STK39 inhibitor ZT-1a enhanced the sensitivity of liver cancer cells HuH-7 and Hep3B to cisplatin and etoposide chemotherapy and reduced cell viability ( Figure 3 AD). STK39 inhibitors ZT-1a and Rafoxanide also enhanced the effects of cisplatin and etoposide chemotherapy on ovarian cancer cells A2780, OVCAR-8, and HO-8910 ( Figure 3 EP).

[0058] 4. Cell experiments have shown that STK39 inhibitors can enhance the sensitivity of pancreatic cancer cells to radiotherapy.

[0059] Clonogenic assays demonstrated that the STK39 inhibitor ZT-1a reduced the survival of PANC-1 and SW1990 cells in response to radiation-induced DNA damage ( Figure 4 AB).

[0060] 5. Cell experiments have shown that STK39 inhibitors can enhance the therapeutic effect of PARPi on ovarian cancer cells and pancreatic cancer cells.

[0061] Clonogenic assays demonstrated that olaparib and the STK39 inhibitor ZT-1a had synergistic effects in cell lines with high STK39 content (PANC-1 and SW1990). Figure 5 AB). Cell activity experiments demonstrated that STK39 inhibitors ZT-1a and Rafoxanide also enhanced the sensitivity of ovarian cancer cells A2780, OVCAR-8, and HO-8910 to olaparib.

[0062] 6. The mouse model demonstrated that the combination of STK39 inhibitor and PARPi can enhance the effect of PARPi in killing pancreatic cancer.

[0063] In cell-derived xenograft (CDX) models of PANC-1 and SW1990 cell lines, olaparib combined with STK39 inhibitors significantly inhibited tumor growth ( Figure 6 AF). In addition, the combination of olaparib and STK39 inhibitors reduced the proliferation potential and increased the apoptotic rate in the CDX model treated with olaparib ( Figure 6 GL).

[0064] In patient-derived xenograft (PDX) models, the combination of olaparib and STK39 inhibitors significantly improved the efficacy of olaparib ( Figure 7 AF). This combined strategy significantly reduced tumor proliferation potential and increased apoptotic tendency ( Figure 7 These findings confirm that STK39 inhibition enhances the sensitivity of pancreatic cancer to PARPi and suggest a promising combination therapy strategy.

[0065] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of STK39 inhibitor as the sole active ingredient in the preparation of drugs for treating tumors.

2. The use of STK39 inhibitors as the sole active ingredient in the preparation of drugs that inhibit the proliferation and invasion ability of tumor cells.

3. The use according to claim 1 or 2, characterized in that: The STK39 inhibitor includes ZT-1a, Rafoxanide or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-2.

4. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a STK39 inhibitor and a PARP inhibitor.

5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a STK39 inhibitor and a chemotherapeutic drug.

6. The pharmaceutical composition according to claim 4 or 5, characterized in that The STK39 inhibitor includes ZT-1a, Rafoxanide or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-2.

7. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises a STK39 inhibitor or a combination of a STK39 inhibitor and a PARP inhibitor or a combination of a STK39 inhibitor and a chemotherapeutic drug.

8. A radio / chemotherapy sensitizer, characterized in that: Contains a STK39 inhibitor.

9. The pharmaceutical preparation according to claim 7 or the radio / chemotherapy sensitizer according to claim 8, characterized in that: The STK39 inhibitor includes ZT-1a, Rafoxanide or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-2.

10. Use of the pharmaceutical composition according to claims 4-5, the pharmaceutical preparation according to claim 7, or the radio / chemotherapy sensitizer according to claim 8 in the preparation of a drug for treating tumors.

Citation Information

Patent Citations

  • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

    CN102341394B

  • Treating cancer with combination products containing PARP inhibitors

    CN110087730B

  • SPAK kinase inhibitors as neuroprotective agents

    US11414379B2

  • Treatment cancers using combination comprising PARP inhibitors

    CN110087730A

  • Sensitizer drug, pharmaceutical composition and application

    CN111671902A